Effect of Intranasal Insulin on LH Concentrations in Man

Status Completed

Clinical Trial Summary

Over the last few years, studies have shown that men with type 2 diabetes sometimes develop a condition called hypogonadotrophic hypogonadism (HH). People with this condition produce little or no sex hormones. Obesity and metabolic syndrome are also associated with HH. Research suggests that insulin in the brain may benefit the glands that release these hormones. During this study, subjects will spray a small amount of insulin into their nose.This will increase insulin concentrations in the brain. The purpose of this study is to find out the effect of one dose of intranasal insulin on release of LH (a sex hormone) in obese diabetic men with HH.

Clinical Trial Description

Studies over the last few years have clearly established that at least 25% of men with type 2 diabetes have subnormal free testosterone (T) concentrations in association with inappropriately low leutinizing hormone (LH) and FSH (follicle stimulating hormone) concentrations. These patients thus suffer from hypogonadotrophic hypogonadism (HH). Obesity and metabolic syndrome are also associated with HH. Animal studies and in vitro data have shown that insulin action and insulin responsiveness in the brain are necessary for the maintenance of the functional integrity of the hypothalamo-hypophyseal-gonadal axis. Insulin concentrations can be increased in the brain by delivering insulin intranasally with vianase device. The aim of this project is to study the effect of one dose of intranasal insulin on release of LH in obese diabetic men with HH. 15 obese men with type 2 diabetes and low free T along with normal LH concentrations will be recruited for the study. The study will be carried out at the clinical center of Texas Tech (Odessa campus). There will be two study visits, each comprising of blood tests every 15 minutes over 6 hours. 40 IU of intranasal insulin or saline will be given after a baseline period of blood sampling of 2 hours. Student's t-test will be used to compare the change in LH concentrations after intranasal saline or insulin. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02154477
Study type	Interventional
Source	Texas Tech University Health Sciences Center
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	December 2014
Completion date	December 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01438073` - Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling	Phase 1
Completed	`NCT01403532` - Sequential Therapy for Hypogonadotropic Hypogonadism	Phase 4
Recruiting	`NCT00456274` - Baselines in Reproductive Disorders	N/A
Terminated	`NCT05205837` - A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial	Phase 4
Completed	`NCT02908074` - A 6 Month Safety Extension Study of MBGS205	Phase 2
Completed	`NCT05752591` - Hypothalamic-pituitary Dysfunction in Diabetes
Terminated	`NCT03118479` - Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)	Phase 1
Completed	`NCT02730169` - Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism	Phase 2
Completed	`NCT02110368` - Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions	Phase 3
Recruiting	`NCT01601171` - Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
Completed	`NCT01623570` - Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP	N/A
Terminated	`NCT00328926` - Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])	Phase 4
Completed	`NCT01438034` - Kisspeptin in the Evaluation of Delayed Puberty	Phase 1
Completed	`NCT04456296` - A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism	Phase 4
Recruiting	`NCT00914823` - Kisspeptin Administration in the Adult	Phase 1
Terminated	`NCT01155518` - Hypogonadism in Young Men With Type 2 Diabetes	Phase 2
Completed	`NCT00697814` - Clomiphene in Males With Prolactinomas and Persistent Hypogonadism	Phase 2
Active, not recruiting	`NCT00351416` - Letrozole Treatment in Normal and GnRH Deficient Women	Phase 2/Phase 3
Recruiting	`NCT05971836` - The Molecular Basis of Inherited Reproductive Disorders
Recruiting	`NCT02705014` - Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.